imi outputs - november 2015

What is €5 billion worth?

Magda Gunn, IMI Scientific Project Manager

Drug discovery is complex

Focus on unmet needs

Non-competitive collaborative

research

Competitive Calls for proposals

Open collaboration in public-private

consortia

Data sharing, dissemination

of results…

Industry contribution is in kind

A partnership between EU

Commission and the European

Federation of Pharmaceutical

Industries and Association

(EFPIA)

Key concepts

Typical IMI project

Industry

ACADEMIA

HOSPITALS

PATIENTS’

ORGANISATIONS

SMALL AND

MEDIUM-SIZED

ENTERPRISES

REGULATORS

Pharma

1

Pharma 2

Pharma

3

Pharma

4

Pharma 5

Pharma

6

Private

Investment

in kind

EU Public

Funding

cash

Many stakeholders many expectations

2.7 billion REMAINING

17 CALLS FOR PROPOSALS

2.6 billion

COMMITTED

68 PROJECTS

0% 5% 10% 15% 20% 25% 30% 35% 40%

Relative Effectiveness

Drug kinetics

Drug delivery

Sustainable chemistry

Lung diseases

Education and Training

Vaccines

Geriatrics

Biologicals

Inflamatory disorders

Cancer

Data Management

Stem cells

Drug safety

Metabolic disorders

Brain disorders

Drug Discovery

Infectious diseases

Performance monitoring framework

Scientific output

Impact on drug development

Impact on regulatory framework

Business opportunities and sustainability

Socio-economic impact

Information, communication and dissemination

Scientific Output

2010 2011 2012 2013 2014

1134 publications by Dec 2014

427 376 224

24%

HIGHLY CITED

1134 PUBLICATIONS

2.19

CITATION IMPACT

9359 CITATIONS

IMI scientific output

Benchmarking

0 0.5 1 1.5 2 2.5

ICMR

World

EU-28

C-Path

CSIRO

GCGH

WT

MRC

FNIH

IMI

Citation impact IMI vs. comparators

0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0

Genetics & Heredity

Psychiatry

Clinical Neurology

Neurosciences

Rheumatology

Biochemistry & Molecular…

Immunology

Pharmacology & Pharmacy

Toxicology

Endocrinology & Metabolism

IMI vs. EU in various research fields

IMI papers EU papers

Collaboration delivers excellence

INTERNATIONAL collaboration

50%

of IMI publications

Collaboration BETWEEN

SECTORS 61% of IMI publications

collaboration BETWEEN INSTITUTIONS

75% of IMI publications

0

1

2

3

Cross-institution Cross-sector International

Citation impact

Collaborative Non-collaborative

Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)

Tracking collaborations across EU Co-authorship between IMI-supported researchers Calls 1-4

Pre IMI funding award Post IMI funding award

Data & analysis: Thomson Reuters (Custom Analytics & Engineered Solutions)

Securing regulatory relevance

Securing regulatory relevance

New standards and best

practices derived from IMI

projects

Number of scientific advice and

qualified opinions initiated by the

IMI projects at the EMA and FDA

Number of regulatory guidelines

derived from IMI projects

Business development and sustainability

IMI project patenting trends 20 patent applications

3.2 patents per €10 million of costs accepted by IMI

Business relevant outputs (n=50)

New Projects

Companies & joint ventures

Foundations & non-profits

Spin-offs breakdown

Job creation as a result of IMI projects

2 272 direct jobs created

13 000 indirect jobs*

* https://researchcouncil.files.wordpress.com/2013/08/walifescienceseconimpactstudy.pdf

Key stakeholder involvement

SMEs receive 18% of IMI funding

15% of IMI participants are SMEs

Promoting SME participation

Thanks to IMI the company went from 6 to 50 employees.

Now they are ready to further expand.

“1st product released to the market in 2013 – IMI was instrumental in

validation of the first cell line product, 2nd product release planned this

year, 3rd diagnostic product in development.

In preparation: a new patent filing to protect technologies for the

creation of third generation human beta cell lines.

www.imi.europa.eu

@IMI_JU

Thank you!

Magda.Gunn@imi.europa.eu